What's new for 'JKB_daily1' in PubMed
This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.
Sender's message: Sepsis or genomics or altitude: JKB_daily1
Sent on Friday, 2014 October 24Search: (sepsis[MeSH Terms] OR septic shock[MeSH Terms] OR altitude[MeSH Terms] OR genomics[MeSH Terms] OR genetics[MeSH Terms] OR retrotransposons[MeSH Terms] OR macrophage[MeSH Terms]) AND ("2009/8/8"[Publication Date] : "3000"[Publication Date]) AND (("Science"[Journal] OR "Nature"[Journal] OR "The New England journal of medicine"[Journal] OR "Lancet"[Journal] OR "Nature genetics"[Journal] OR "Nature medicine"[Journal]) OR (Hume DA[Author] OR Baillie JK[Author] OR Faulkner, Geoffrey J[Author]))
View complete results in PubMed (results may change over time).
Edit saved search settings, or unsubscribe from these e-mail updates.
PubMed Results |
1. | Nature. 2014 Oct 2;514(7520):E2. doi: 10.1038/nature13689.Kruidenier et al. reply.Kruidenier L1, Chung CW2, Cheng Z3, Liddle J1, Che K4, Joberty G5, Bantscheff M5, Bountra C6, Bridges A2, Diallo H1, Eberhard D5, Hutchinson S2, Jones E2, Katso R2, Leveridge M2, Mander PK1, Mosley J2, Ramirez-Molina C1, Rowland P2, Schofield CJ6, Sheppard RJ1, Smith JE1, Swales C7, Tanner R2, Thomas P2, Tumber A6, Drewes G5, Oppermann U4, Patel DJ3, Lee K8, Wilson DM1.Author information: Comment on |
PMID: 25279927 [PubMed - indexed for MEDLINE] | |
Related citations | |
![]() |
2. | Nature. 2014 Oct 2;514(7520):E1-2. doi: 10.1038/nature13688.Inhibition of demethylases by GSK-J1/J4.Heinemann B1, Nielsen JM1, Hudlebusch HR1, Lees MJ2, Larsen DV1, Boesen T1, Labelle M1, Gerlach LO1, Birk P1, Helin K3.Author information: Comment in
Comment on |
PMID: 25279926 [PubMed - indexed for MEDLINE] | |
Related citations | |
![]() |
3. | Nature. 2014 Oct 2;514(7520):59-64. doi: 10.1038/nature13786.Biogeography and individuality shape function in the human skin metagenome.Oh J1, Byrd AL1, Deming C1, Conlan S1; NISC Comparative Sequencing Program, Kong HH2, Segre JA3.Collaborators: Barnabas B, Blakesley R, Bouffard G, Brooks S, Coleman H, Dekhtyar M, Gregory M, Guan X, Gupta J, Han J, Ho SL, Legaspi R, Maduro Q, Masiello C, Maskeri B, McDowell J, Montemayor C, Mullikin J, Park M, Riebow N, Schandler K, Schmidt B, Sison C, Stantripop M, Thomas J, Thomas P, Vemulapalli M, Young A. Author information: Comment in
AbstractThe varied topography of human skin offers a unique opportunity to study how the body's microenvironments influence the functional and taxonomic composition of microbial communities. Phylogenetic marker gene-based studies have identified many bacteria and fungi that colonize distinct skin niches. Here metagenomic analyses of diverse body sites in healthy humans demonstrate that local biogeography and strong individuality define the skin microbiome. We developed a relational analysis of bacterial, fungal and viral communities, which showed not only site specificity but also individual signatures. We further identified strain-level variation of dominant species as heterogeneous and multiphyletic. Reference-free analyses captured the uncharacterized metagenome through the development of a multi-kingdom gene catalogue, which was used to uncover genetic signatures of species lacking reference genomes. This work is foundational for human disease studies investigating inter-kingdom interactions, metabolic changes and strain tracking, and defines the dual influence of biogeography and individuality on microbial composition and function. |
PMID: 25279917 [PubMed - indexed for MEDLINE] | |
Related citations | |
![]() |
4. | Nature. 2014 Oct 2;514(7520):24-6. doi: 10.1038/514024a.The first South Americans: Extreme living.Fraser B. |
PMID: 25279901 [PubMed - indexed for MEDLINE] | |
Related citations | |
![]() |
5. | Nature. 2014 Oct 2;514(7520):16-7. doi: 10.1038/514016a.Tibetan plateau gets wired up for monsoon prediction.Qiu J. |
PMID: 25279896 [PubMed - indexed for MEDLINE] | |
Related citations | |
![]() |
6. | Nature. 2014 Oct 2;514(7520):13-4. doi: 10.1038/514013a.Fast genetic sequencing saves newborn lives.Reardon S. |
PMID: 25279893 [PubMed - indexed for MEDLINE] | |
Related citations | |
![]() |
7. | Science. 2014 Sep 26;345(6204):1251086. doi: 10.1126/science.1251086.Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity.Saeed S1, Quintin J2, Kerstens HH1, Rao NA1, Aghajanirefah A1, Matarese F1, Cheng SC2, Ratter J2, Berentsen K1, van der Ent MA1, Sharifi N1, Janssen-Megens EM1, Ter Huurne M1, Mandoli A1, van Schaik T1, Ng A3, Burden F4, Downes K4, Frontini M4, Kumar V5, Giamarellos-Bourboulis EJ6, Ouwehand WH4, van der Meer JW2, Joosten LA2, Wijmenga C5, Martens JH1, Xavier RJ3, Logie C7, Netea MG8, Stunnenberg HG7.Author information: AbstractMonocyte differentiation into macrophages represents a cornerstone process for host defense. Concomitantly, immunological imprinting of either tolerance or trained immunity determines the functional fate of macrophages and susceptibility to secondary infections. We characterized the transcriptomes and epigenomes in four primary cell types: monocytes and in vitro-differentiated naïve, tolerized, and trained macrophages. Inflammatory and metabolic pathways were modulated in macrophages, including decreased inflammasome activation, and we identified pathways functionally implicated in trained immunity. β-glucan training elicits an exclusive epigenetic signature, revealing a complex network of enhancers and promoters. Analysis of transcription factor motifs in deoxyribonuclease I hypersensitive sites at cell-type-specific epigenetic loci unveiled differentiation and treatment-specific repertoires. Altogether, we provide a resource to understand the epigenetic changes that underlie innate immunity in humans. Copyright © 2014, American Association for the Advancement of Science. |
PMID: 25258085 [PubMed - indexed for MEDLINE] | |
Related citations | |
![]() |
8. | Science. 2014 Sep 26;345(6204):1250684. doi: 10.1126/science.1250684.mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity.Cheng SC1, Quintin J1, Cramer RA2, Shepardson KM2, Saeed S3, Kumar V4, Giamarellos-Bourboulis EJ5, Martens JH3, Rao NA3, Aghajanirefah A3, Manjeri GR6, Li Y4, Ifrim DC1, Arts RJ1, van der Meer BM4, Deen PM7, Logie C3, O'Neill LA8, Willems P6, van de Veerdonk FL1, van der Meer JW1, Ng A9, Joosten LA1, Wijmenga C4, Stunnenberg HG4, Xavier RJ9, Netea MG10.Author information: AbstractEpigenetic reprogramming of myeloid cells, also known as trained immunity, confers nonspecific protection from secondary infections. Using histone modification profiles of human monocytes trained with the Candida albicans cell wall constituent β-glucan, together with a genome-wide transcriptome, we identified the induced expression of genes involved in glucose metabolism. Trained monocytes display high glucose consumption, high lactate production, and a high ratio of nicotinamide adenine dinucleotide (NAD(+)) to its reduced form (NADH), reflecting a shift in metabolism with an increase in glycolysis dependent on the activation of mammalian target of rapamycin (mTOR) through a dectin-1-Akt-HIF-1α (hypoxia-inducible factor-1α) pathway. Inhibition of Akt, mTOR, or HIF-1α blocked monocyte induction of trained immunity, whereas the adenosine monophosphate-activated protein kinase activator metformin inhibited the innate immune response to fungal infection. Mice with a myeloid cell-specific defect in HIF-1α were unable to mount trained immunity against bacterial sepsis. Our results indicate that induction of aerobic glycolysis through an Akt-mTOR-HIF-1α pathway represents the metabolic basis of trained immunity. Copyright © 2014, American Association for the Advancement of Science. |
PMID: 25258083 [PubMed - indexed for MEDLINE] | |
Related citations | |
![]() |
9. | Nature. 2014 Oct 2;514(7520):47-53. doi: 10.1038/nature13777. Epub 2014 Aug 29.Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.Qiu X1, Wong G2, Audet J2, Bello A2, Fernando L1, Alimonti JB1, Fausther-Bovendo H2, Wei H3, Aviles J1, Hiatt E4, Johnson A4, Morton J4, Swope K4, Bohorov O5, Bohorova N5, Goodman C5, Kim D5, Pauly MH5, Velasco J5, Pettitt J6, Olinger GG6, Whaley K5, Xu B7, Strong JE8, Zeitlin L5, Kobinger GP9.Author information: Comment inAbstractWithout an approved vaccine or treatments, Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission. These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in West Africa. Here we show that a combination of monoclonal antibodies (ZMapp), optimized from two previous antibody cocktails, is able to rescue 100% of rhesus macaques when treatment is initiated up to 5 days post-challenge. High fever, viraemia and abnormalities in blood count and blood chemistry were evident in many animals before ZMapp intervention. Advanced disease, as indicated by elevated liver enzymes, mucosal haemorrhages and generalized petechia could be reversed, leading to full recovery. ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola. ZMapp exceeds the efficacy of any other therapeutics described so far, and results warrant further development of this cocktail for clinical use. |
PMID: 25171469 [PubMed - indexed for MEDLINE] | |
Related citations | |
![]() |
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home